NCT06286631 Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
| NCT ID | NCT06286631 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital of Xi'an Jiaotong University |
| Condition | Papillary Thyroid Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2023-05-01 |
| Primary Completion | 2025-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2023-05-01 with a primary completion date of 2025-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The incidence of papillary thyroid cancer (PTC) has been on the rise in recent years, and 20%-50% of PTC patients will have lymph node metastasis. Lymph node involvement in PTC patients is usually related to the recurrence of PTC after surgery, and 30% of patients recur without lymph node dissection, with the risk of central cervical lymph node metastasis being the greatest, so it seems to be a good choice to perform lymph node dissection on patients after thyroidectomy, but in fact, there are controversies at home and abroad as to whether to perform lymph node dissection or not. The 2021 Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of differentiated thyroid cancer state that prophylactic central lymph node dissection (PCND) may increase the incidence of postoperative complications, but due to the high metastatic rate of PTC and the ability of PCND to effectively prevent recurrence and reoperation, countries in the East Asian region perform prophylactic lymph node dissection on almost all patients with PTC. However, for more countries in Europe and the United States, performing PCND has become a non-essential, individualized option. The aim of this study is to collect multifactorial data from more than 1,000 patients who have undergone previous thyroidectomy from 2021 to 2023, and to develop a novel scoring scale that can be used to individualize patients' scores based on a variety of factors prior to surgery, so that patients can be more accurately predicted to have lymph node metastasis and need prophylactic lymph node dissection prior to surgery, and patients who do not need dissection can avoid surgery. For patients who do not need lymph node dissection, complications caused by surgery can be avoided, while for patients who do have lymph node metastasis, recurrence of their cancer can be prevented. This will change the status quo of not being able to accurately determine the actual situation through simple preoperative examination or performing prophylactic lymph node dissection for all PTC patients.
Eligibility Criteria
Inclusion Criteria: * Papillary thyroid cancer * Conscious and able to communicate normally * Age 16-80 years Exclusion Criteria: * Preoperative or postoperative pathology suggests other types of tumors, such as medullary carcinoma or undifferentiated carcinoma. * Less than 16 years of age
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06286631 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 80 Years, studying Papillary Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06286631 currently recruiting?
Yes, NCT06286631 is actively recruiting participants. Contact the research team at individualliu@163.com for enrollment information.
Where is the NCT06286631 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT06286631 clinical trial?
NCT06286631 is sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.